NCT05900102Completed
Head and Neck Melanoma; Access to Staging and Surgical Treatment
Evaluating the Current Standard of Care for Patients Diagnosed With Malignant Melanoma of the Head and Neck - Access to Staging and Surgical Treatment
Source: ClinicalTrials.gov · Last updated 4 Apr 2025
Brief summary (registry, in English)
Melanoma is a serious type of skin cancer and is the 5th most common cancer in the United Kingdom (UK). It can affect anywhere on the skin including on the head and neck. The cancer often is first noticed as an abnormal mole. Treatment is by removing the cancer with surgery. Early spread of the cancer can be found by testing nearby glands called lymph nodes. This operation is called a sentinel lymph node biopsy (SLNB). If the cancer has spread then new treatments, such as immunotherapy, can be given to help the person live for longer. The sentinel lymph nodes are usually in the armpits or groin for melanoma on the body, arms or legs. For cancers in the head and neck the sentinel lymph nodes will usually be in the neck. For several reasons SLNB in the neck is not offered in every hospital that manages patients with melanoma. The problem with this is that some patients who could benefit are not offered the new treatments that extend life because it is not known that their cancer has spread. In this study we aim to gather national data on the management of melanoma of the head and neck including variation in practice between different hospitals. We will use routinely collected anonymous data called 'Hospital Episode Statistics' to look at who is offered SLNB after melanoma of the head or neck, what treatments they have, if their melanoma comes back and how long they survive for. By doing this, we hope to identify whether SLNB should be made available to everyone diagnosed with melanoma of the head and neck.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 86000 (actual)
- First submitted
- 2 Jun 2023
- Start date
- 1 Oct 2024
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Hull University Teaching Hospitals NHS Trust
- Diseases
- Melanoma
- NCT number
- NCT05900102
What you commit to
- Study type: Observational
- Participants enrolled: 86000
- From 1 Oct 2024 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- N/A
Who the study is looking for
- We will use recorded ICD-10 codes to identify patients for the study. All patients over 18 years of age will be included in the study if they have been coded as:
- C43.0 Malignant melanoma of lip C43.1 Malignant melanoma of eyelid, including canthus C43.2 Malignant melanoma of ear and external auricular canal C43.3 Malignant melanoma of other and unspecified parts of face C43.4 Malignant melanoma of scalp and neck C43.5 Malignant melanoma of trunk C43.6 Malignant melanoma of upper limb, including shoulder C43.7 Malignant melanoma of lower limb, including hip
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Academic Plastic Surgery, Hull University Teaching Hospitals NHS TRust Coordinator of this site? Confirm its status | Cottingham | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.